Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Azetidine compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders

Azetidine compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders

US Patent 10392366 · Granted Aug 27, 2019

Estimated economic value: $5,462,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Isoxazolidines as RIPK1 inhibitors and use thereof2024
Isoindolinone compounds as GPR119 modulators for the treatment of diabetes, obes2018
Isoindolinone compounds as GPR119 modulators for the treatment of diabetes, obes2018
Isoindolinone compounds as GPR119 modulators for the treatment of diabetes, obes2018
Isoindolinone compounds as GPR119 modulators for the treatment of diabetes, obes2018
Isoindolinone compounds as GPR119 modulators for the treatment of diabetes, obes2018
Isoindolinone compounds as GPR119 modulators for the treatment of diabetes, obes2018
Isoindolinone compounds as GPR119 modulators for the treatment of diabetes, obes2018
Substituted indanone compounds as GPR119 modulators for the treatment of diabete2018
Substituted indanone compounds as GPR119 modulators for the treatment of diabete2018
Substituted indanone compounds as GPR119 modulators for the treatment of diabete2018
Substituted indanone compounds as GPR119 modulators for the treatment of diabete2018